Catalyst Pharmaceuticals Inc (CPRX)
Official siteBIOTECHNOLOGY
Last updated: Jul 16, 2026 at 5:00 PM ET
Catalyst Pharmaceuticals Inc (CPRX) Financials: Revenue, Profit and Cash Flow
Catalyst Pharmaceuticals reported revenue of $588.99M for the fiscal year ended Dec 31, 2025, up 19.8% from the year before. That year, net income was $214.33M with a net margin of 36.4%, operating cash flow was $208.67M and free cash flow was $208.61M. The quarter ended Mar 31, 2026 had revenue of $149.39M and net income of $63.73M.
Revenue and Margins
The operating margin was 43.8% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $500.00K, a compound annual rate of 174.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $588.99M | +19.8% | 85.2% | 43.8% | 36.4% |
| Dec 2024 | $491.73M | +23.5% | 86.0% | 39.7% | 33.3% |
| Dec 2023 | $398.20M | +85.9% | 86.9% | 21.8% | 17.9% |
| Dec 2022 | $214.20M | +52.1% | 83.9% | 47.5% | 38.8% |
| Dec 2021 | $140.83M | +18.3% | 84.5% | 37.2% | 28.0% |
| Dec 2020 | $119.07M | +16.4% | 85.7% | 34.7% | 63.0% |
| Dec 2019 | $102.31M | +20361.2% | 85.6% | 31.1% | 31.2% |
| Dec 2018 | $500.00K | N/A | 100.0% | -7059.0% | -6800.7% |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income rose 30.8% from the year before. In the quarter ended Mar 2026, net income rose 12.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $588.99M | $491.73M | $398.20M | $214.20M | $140.83M | $119.07M | $102.31M | $500.00K | $0 | $0 |
| Cost of revenue | $87.25M | $68.84M | $51.97M | $34.39M | $21.88M | $17.04M | $14.76M | $0 | $0 | $0 |
| Gross profit | $501.74M | $422.89M | $346.24M | $179.81M | $118.95M | $102.03M | $87.55M | $500.00K | $0 | $0 |
| Research and development | $12.71M | $12.65M | $93.15M | $19.79M | $16.94M | $16.50M | $18.84M | $19.92M | $11.38M | $11.37M |
| Operating income | $257.78M | $195.12M | $86.81M | $101.84M | $52.38M | $41.30M | $31.82M | -$35.30M | -$18.68M | -$19.28M |
| Net income | $214.33M | $163.89M | $71.41M | $83.08M | $39.48M | $74.98M | $31.88M | -$34.00M | -$18.41M | -$18.07M |
| EBITDA | $321.39M | $254.04M | $127.39M | $105.96M | $52.86M | $41.98M | $33.71M | -$33.97M | -$18.37M | -$18.03M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $149.39M | $152.61M | $148.39M | $146.56M | $141.42M | $141.82M | $128.69M | $122.71M | $98.51M | $110.57M | $102.69M | $99.58M |
| Gross profit | $134.91M | $126.54M | $125.74M | $125.95M | $123.51M | $120.18M | $109.42M | $107.31M | $85.99M | $94.76M | $88.52M | $87.54M |
| Operating income | $73.23M | $61.85M | $66.27M | $66.30M | $63.37M | $62.84M | $50.91M | $54.25M | $27.13M | $41.69M | -$37.19M | $46.70M |
| Net income | $63.73M | $52.70M | $52.78M | $52.11M | $56.74M | $55.94M | $43.88M | $40.79M | $23.27M | $34.84M | -$30.76M | $37.76M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $437.00K by $708.73M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.10B | $851.41M | $470.11M | $375.63M | $237.79M | $192.35M | $112.38M | $60.45M | $85.39M | $41.71M |
| Current assets | $894.03M | $623.61M | $219.33M | $320.81M | $210.11M | $159.24M | $111.36M | $55.19M | $85.19M | $41.45M |
| Cash and equivalents | $709.17M | $517.55M | $137.64M | $298.39M | $171.44M | $130.24M | $89.51M | $16.56M | $57.50M | $13.89M |
| Total liabilities | $149.71M | $123.78M | $82.23M | $75.21M | $30.96M | $22.76M | $24.75M | $9.67M | $4.42M | $2.40M |
| Short-term debt | $437.00K | $402.00K | $369.00K | $337.00K | $308.00K | $29.00K | $300.52K | N/A | N/A | N/A |
| Shareholder equity | $954.27M | $727.63M | $387.88M | $300.42M | $206.83M | $169.60M | $87.63M | $50.78M | $80.96M | $39.31M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.15B | $1.11B | $1.05B | $971.91M | $908.87M | $851.41M | $772.01M | $706.36M | $646.68M | $470.11M | $413.21M | $443.90M |
| Total liabilities | $134.91M | $152.54M | $131.36M | $115.89M | $114.59M | $123.78M | $111.07M | $97.70M | $85.26M | $82.23M | $64.66M | $68.60M |
| Cash and equivalents | $755.86M | $709.17M | $689.89M | $652.80M | $580.66M | $517.55M | $442.33M | $375.69M | $310.41M | $137.64M | $120.97M | $178.79M |
| Shareholder equity | $1.01B | $954.27M | $920.25M | $856.03M | $794.28M | $727.63M | $660.94M | $608.65M | $561.41M | $387.88M | $348.55M | $375.29M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow. Share repurchases came to 12.1% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $208.67M | $239.81M | $143.60M | $116.05M | $60.37M | $45.03M | $34.61M | -$26.15M | -$13.74M | -$17.96M |
| Capital expenditures | $58.00K | $556.00K | $231.00K | $29.00K | $1.02M | $11.00K | $19.00K | $92.02K | $92.02K | $96.06K |
| Free cash flow | $208.61M | $239.25M | $143.37M | $116.02M | $59.35M | $45.02M | $34.59M | -$26.24M | -$13.83M | -$18.06M |
| Share repurchases | $25.30M | $296.00K | $0 | $6.91M | $12.09M | $0 | $0 | N/A | N/A | N/A |
| Investing cash flow | -$58.00K | -$556.00K | -$293.50M | $9.21M | -$11.02M | -$5.01M | $37.23M | -$15.08M | -$3.96K | $3.55M |
| Financing cash flow | -$16.99M | $140.66M | -$10.86M | $1.69M | -$8.14M | $702.00K | $1.12M | $293.12K | $57.35M | $68.99K |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $59.59M | $44.89M | $32.44M | $71.30M | $60.04M | $70.88M | $72.87M | $64.14M | $31.93M | $55.65M | $45.13M | $30.75M |
| Capital expenditures | $27.00K | $32.00K | $0 | $26.00K | $0 | $88.00K | $259.00K | $10.00K | $199.00K | $93.00K | $64.00K | $0 |
| Free cash flow | $59.56M | $44.86M | $32.44M | $71.27M | $60.04M | $70.79M | $72.61M | $64.13M | $31.73M | $55.55M | $45.06M | $30.75M |
Frequently Asked Questions About CPRX
What is Catalyst Pharmaceuticals' annual revenue?
Catalyst Pharmaceuticals reported revenue of $588.99M for the fiscal year ended Dec 31, 2025.
How fast is Catalyst Pharmaceuticals' revenue growing?
Revenue was up 19.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 40.1%.
Is Catalyst Pharmaceuticals profitable?
Yes. Catalyst Pharmaceuticals reported net income of $214.33M for the fiscal year ended Dec 31, 2025, with a net margin of 36.4%.
How much free cash flow does CPRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $208.67M minus capital expenditures of $58.00K produced free cash flow of $208.61M.
How much debt does Catalyst Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $437.00K and cash and equivalents of $709.17M.
CPRX pages: Overview, Financials